<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02794844</url>
  </required_header>
  <id_info>
    <org_study_id>744230</org_study_id>
    <nct_id>NCT02794844</nct_id>
  </id_info>
  <brief_title>Implementation of PPI Medication PGX Testing</brief_title>
  <acronym>PGX</acronym>
  <official_title>Implementation of Pharmacogenomic Testing in Nemours Children's Health System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nemours Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nemours Children's Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using genetic information about the individual to pick the right drug for the right disease&#xD;
      at the right dose defines personalized medicine. This pilot study seeks to institute&#xD;
      pharmacogenomic testing, that is identifying genetic variation that influences patient&#xD;
      response to drugs, into the Nemours Children's Health system. We propose to initiate the&#xD;
      study by identifying genetic differences in cyp2c19, a gene that is responsible for a certain&#xD;
      enzyme in the liver that metabolizes many drugs including a class of drugs called proton pump&#xD;
      inhibitors (ppi; Prevacid, Nexium). PPIs are used to treat heartburn and other symptoms of&#xD;
      gastroesophageal reflux disease (gerd) and are extensively used in pediatrics. Chronic use of&#xD;
      PPIs can cause serious side effects including cold, pneumonia and stomach infections, which&#xD;
      gets worse at higher doses. Children who poorly metabolize drugs because of genetic variation&#xD;
      in cyp2c19 should get lower doses of PPIs than children who metabolize PPIs normally. Our&#xD;
      pilot study will genotype children with gerd or other stomach acid mediated conditions for&#xD;
      which a PPI is prescribed using a sample of spit to determine which dose of PPI they get&#xD;
      based on the form of the cyp2c19 gene they have. We will study 120 children 2-17 yo diagnosed&#xD;
      with gastroesophageal reflux disease (gerd) or other stomach acid mediated conditions for&#xD;
      which a ppi is prescribed . Genetic results are available in &lt; 60 minutes, and their doses&#xD;
      are determined by their doctor based on genetic results. This study will allow us to gain&#xD;
      valuable experience that will be used to expand our genetic program to other genes and drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long-term objective of this research is to implement pharmacogenomic (PGX) testing of&#xD;
      approved gene-drug pairs to maximize the efficacy and minimize adverse events for drugs that&#xD;
      are used to treat childhood disease. Personalized medicine, that is, the use of the patient's&#xD;
      own genetic information to predict the right dose of the right drug, has been a goal of&#xD;
      medicine's since the publication of the human genome and HAPMAP projects. However, the&#xD;
      adoption of PGX testing has been slow owing to several barriers and challenges. Recently&#xD;
      President Obama announced the precision medicine initiative, which includes PGX testing, and&#xD;
      has earmarked $ 1 b to implement it. The precision medicine initiative is expected to move&#xD;
      personalized medicine forward so that most patients including pediatric patients will&#xD;
      benefit. The Nemours Children's Health System is uniquely positioned to lead the effort to&#xD;
      personalize medicine among pediatric patients. The goal of the proposed 1-year pilot project&#xD;
      is to implement PGX testing in the Nemours children's health system. The experience,&#xD;
      knowledge and skills gained in this pilot project will position Nemours to help lead&#xD;
      precision medicine initiatives including PGX testing among pediatric populations. To&#xD;
      implement PGX testing in Nemours we propose to begin testing the cyp2c19 - proton pump&#xD;
      inhibitor gene-drug pair in the division of gastroenterology, Nemours children's hospital. A&#xD;
      total of 120 children 2-17 yo who have been diagnosed with gastroesophageal reflux disease&#xD;
      (GERD) or other stomach acid mediated conditions for which a PPI is prescribed will be&#xD;
      recruited into the study by pediatric gastroenterologists (aim 1a). Drs. Franciosi and Lima&#xD;
      will educate staff in the division of PGX testing and of the study. GI pediatricians are not&#xD;
      required to participate in PGX testing. After obtaining consent, the study coordinator will&#xD;
      obtain and bar code samples of saliva from the patient. Samples will be genotyped by Spartan&#xD;
      Rx, a point-of-care genotyping platform, which are housed (2 of them) in the division of&#xD;
      pathology. Loss-of-function alleles (*2, *3) and the gain-of-function allele (*17) are&#xD;
      identified in &lt; 60 minutes. The result of genotyping will be checked by dr. Badizadegan and&#xD;
      entered into the patient's EMR. Clinical Decision Support (CDS) tools will advise Drs.&#xD;
      Badizadegan and Franciosi of the patient's metabolic phenotype based on cyp2c19 genotype. Dr.&#xD;
      Franciosi (or other GI pediatricians) will decide the dose of PPI to use based CDS tools&#xD;
      carrying algorithms for conventional dosing and for genotype-guided dosing of PPIs. The&#xD;
      electronic prescription for the PPI with genotype-guided dosing will be called in. PPI&#xD;
      efficacy and safety for each study participant will be monitored weekly (aim 1B) by&#xD;
      collecting and recording scores on validated GERD and adverse reaction questionnaires.&#xD;
      Efficacy and safety scores will be communicated by each participant (or caregiver) using&#xD;
      mobile devices (iPhone; computer) and recorded using redcap. Dr. Blake will supervise this&#xD;
      phase of the study. Outcome metrics for aim 1A include: % of patients agreeing to volunteer&#xD;
      for the study; % of patients reporting efficacy and toxicity data; % of providers agreeing to&#xD;
      participate in study; and % of participants agreeing to future use of DNA. Outcome metrics&#xD;
      for aim B will be judgments by Dr. Franciosi and his staff regarding success based on scores&#xD;
      from GERD and adverse event questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 21, 2016</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">January 23, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Count of Patients Agreeing to Volunteer for the Study</measure>
    <time_frame>Through 12 months study</time_frame>
    <description>Outcomes for evaluating the success of PGX implementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Count of Patients Reporting Efficacy and Toxicity Data</measure>
    <time_frame>Throughout 12 month study</time_frame>
    <description>Outcomes for evaluating the success of PGX implementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Count of Providers Agreeing to Participate in Study</measure>
    <time_frame>Throughout 12 month study</time_frame>
    <description>Outcomes for evaluating the success of PGX implementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Count of Participants Agreeing to Future Use of DNA</measure>
    <time_frame>Throughout 12 month study</time_frame>
    <description>Outcomes for evaluating the success of PGX implementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Effects After Genotype-guided PPI Therapy</measure>
    <time_frame>Throughout 12 month study</time_frame>
    <description>Count of participants reporting adverse effects after genotype-guided PPI therapy.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Genotype Guided PPI Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.&#xD;
No other ARM will be studied.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genotype Guided PPI Dosing</intervention_name>
    <description>Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.</description>
    <arm_group_label>Genotype Guided PPI Dosing</arm_group_label>
    <other_name>Prilosec</other_name>
    <other_name>Nexium</other_name>
    <other_name>Prevacid</other_name>
    <other_name>Proton Pump Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children diagnosed with Gastroesophageal Reflux Disease (GERD) or a stomach acid&#xD;
             mediated condition for which a PPI is prescribed.&#xD;
&#xD;
          -  Currently taking or will be prescribed Proton Pump Inhibitor (PPI) medication&#xD;
&#xD;
          -  Parents/legal guardians and or child must also have access to the internet and a valid&#xD;
             email address to complete weekly required forms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children who have had peptic ulcer surgery;&#xD;
&#xD;
          -  with a history of PKU&#xD;
&#xD;
          -  with a history of previous adverse effects from PPI treatment or a sensitivity to&#xD;
             aspartame (NutraSweet, Equal);&#xD;
&#xD;
          -  who are non-adherent including inability or unwillingness of the legal guardian to&#xD;
             provide consent of unwillingness of the child to provide assent;&#xD;
&#xD;
          -  who are unable to take study medications;&#xD;
&#xD;
          -  who are unable to communicate via telephone or other device;&#xD;
&#xD;
          -  who do not have access to a computer with internet access&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James P Franciosi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemours Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2016</study_first_posted>
  <results_first_submitted>April 9, 2018</results_first_submitted>
  <results_first_submitted_qc>April 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2018</results_first_posted>
  <last_update_submitted>October 24, 2018</last_update_submitted>
  <last_update_submitted_qc>October 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nemours Children's Clinic</investigator_affiliation>
    <investigator_full_name>James Franciosi</investigator_full_name>
    <investigator_title>Principle Research Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 10, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02794844/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From 06/16/2015 to 02/20/2017, patients (or in the case of children, the pediatric patient and their parent/legal guardian) were approached for participation after a clinical assessment was performed by a GI provider during an outpatient GI appointment. Study procedures were performed after obtaining proper consent and/or child assent.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Genotype Guided PPI Dosing</title>
          <description>Genotype Guided PPI Dosing: PPI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.&#xD;
No other ARM will be studied.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Genotype Guided PPI Dosing</title>
          <description>Genotype Guided PPI Dosing: PPI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.&#xD;
No other ARM will be studied.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metabolizer Phenotype Frequency</title>
          <description>Depending on the CYP2C19 genotype individuals are classified into different phenotypes: poor metabolizer (PM), intermediate metabolizers (IM), normal metabolizers (NM), rapid metabolizer (RM) and ultra-rapid metabolizers (UM).&#xD;
Allele Genotype/Activity Phenotype&#xD;
1/*1 -2 active alleles NM&#xD;
1/n -1 active, 1 LOF allele IM&#xD;
2/*2 or *n*n -2 LOF alleles PM&#xD;
1/*17 -1 active, 1 GOF allele RM&#xD;
17/*17 -2 GOF alleles UM</description>
          <population>Results were inconclusive for 5 participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Slow Metabolizers (IM and PM)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal Metabolizers (NM)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fast Metabolizers (EM and UM)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Count of Patients Agreeing to Volunteer for the Study</title>
        <description>Outcomes for evaluating the success of PGX implementation</description>
        <time_frame>Through 12 months study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype Guided PPI Dosing</title>
            <description>Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.&#xD;
No other ARM will be studied.&#xD;
Genotype Guided PPI Dosing: Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Patients Agreeing to Volunteer for the Study</title>
          <description>Outcomes for evaluating the success of PGX implementation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Count of Patients Reporting Efficacy and Toxicity Data</title>
        <description>Outcomes for evaluating the success of PGX implementation</description>
        <time_frame>Throughout 12 month study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype Guided PPI Dosing</title>
            <description>Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.&#xD;
No other ARM will be studied.&#xD;
Genotype Guided PPI Dosing: Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Patients Reporting Efficacy and Toxicity Data</title>
          <description>Outcomes for evaluating the success of PGX implementation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Count of Providers Agreeing to Participate in Study</title>
        <description>Outcomes for evaluating the success of PGX implementation</description>
        <time_frame>Throughout 12 month study</time_frame>
        <population>6 providers participated in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype Guided PPI Dosing</title>
            <description>Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.&#xD;
No other ARM will be studied.&#xD;
Genotype Guided PPI Dosing: Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Providers Agreeing to Participate in Study</title>
          <description>Outcomes for evaluating the success of PGX implementation</description>
          <population>6 providers participated in the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Count of Participants Agreeing to Future Use of DNA</title>
        <description>Outcomes for evaluating the success of PGX implementation</description>
        <time_frame>Throughout 12 month study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype Guided PPI Dosing</title>
            <description>Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.&#xD;
No other ARM will be studied.&#xD;
Genotype Guided PPI Dosing: Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants Agreeing to Future Use of DNA</title>
          <description>Outcomes for evaluating the success of PGX implementation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Effects After Genotype-guided PPI Therapy</title>
        <description>Count of participants reporting adverse effects after genotype-guided PPI therapy.</description>
        <time_frame>Throughout 12 month study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype Guided PPI Dosing</title>
            <description>Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.&#xD;
No other ARM will be studied.&#xD;
Genotype Guided PPI Dosing: Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects After Genotype-guided PPI Therapy</title>
          <description>Count of participants reporting adverse effects after genotype-guided PPI therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Genotype Guided PPI Dosing</title>
          <description>Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.&#xD;
No other ARM will be studied.&#xD;
Genotype Guided PPI Dosing: Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James P. Franciosi, MD</name_or_title>
      <organization>Nemours Children's Hospital</organization>
      <phone>407-567-3832</phone>
      <email>jfrancio@nemours.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

